VIVUS to Present at the 2011 JP Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 5, 2011 /PRNewswire/ — VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 29th Annual JP Morgan Healthcare Conference.
The VIVUS presentation will take place at the Westin St. Francis Hotel in San Francisco, CA on Wednesday, January 12, 2011 at 8:30 a.m. PT. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company’s lead product in clinical development, QNEXAÃ‚®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US regulators. QNEXAÃ‚® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com
CONTACT: -------- Investor VIVUS, Inc. Relations: The Trout Group Timothy E. Morris Brian Korb Chief Financial Officer email@example.com 650-934-5200 646-378-2923
SOURCE VIVUS, Inc.